Medlab Clinical Past Earnings Performance
Past criteria checks 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -27.3%, while the Biotechs industry saw earnings growing at 12.4% annually. Revenues have been declining at an average rate of 6.2% per year.
Key information
-27.3%
Earnings growth rate
-17.2%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | -6.2% |
| Return on equity | -101.4% |
| Net Margin | -268.1% |
| Last Earnings Update | 31 Dec 2021 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Medlab Clinical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 21 | 4 | -12 | 11 | 1 |
| 30 Sep 21 | 4 | -12 | 11 | 2 |
| 30 Jun 21 | 4 | -12 | 11 | 2 |
| 31 Mar 21 | 2 | -11 | 9 | 2 |
| 31 Dec 20 | 1 | -11 | 9 | 2 |
| 30 Sep 20 | 2 | -12 | 9 | 2 |
| 30 Jun 20 | 3 | -13 | 10 | 2 |
| 31 Mar 20 | 4 | -12 | 10 | 2 |
| 31 Dec 19 | 4 | -12 | 11 | 2 |
| 30 Sep 19 | 5 | -10 | 10 | 1 |
| 30 Jun 19 | 5 | -8 | 10 | 1 |
| 31 Mar 19 | 5 | -7 | 8 | 1 |
| 31 Dec 18 | 5 | -6 | 7 | 0 |
| 30 Sep 18 | 4 | -5 | 7 | 0 |
| 30 Jun 18 | 4 | -5 | 6 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 5 | -4 | 6 | 0 |
| 30 Sep 17 | 5 | -4 | 5 | 0 |
| 30 Jun 17 | 4 | -4 | 5 | 0 |
| 31 Mar 17 | 4 | -4 | 5 | 0 |
| 31 Dec 16 | 4 | -4 | 4 | 0 |
| 30 Sep 16 | 3 | -4 | 4 | 0 |
| 30 Jun 16 | 3 | -3 | 4 | 0 |
Quality Earnings: MDCDA is currently unprofitable.
Growing Profit Margin: MDCDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDCDA is unprofitable, and losses have increased over the past 5 years at a rate of 27.3% per year.
Accelerating Growth: Unable to compare MDCDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MDCDA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: MDCDA has a negative Return on Equity (-101.43%), as it is currently unprofitable.